These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10064262)

  • 1. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy.
    Moyle GJ; Sadler M; Buss N
    Clin Infect Dis; 1999 Feb; 28(2):403-4. PubMed ID: 10064262
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Garlic supplements found to lower saquinavir levels.
    TreatmentUpdate; 2001; 12(12):17-8. PubMed ID: 11570085
    [No Abstract]   [Full Text] [Related]  

  • 4. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
    Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
    AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
    [No Abstract]   [Full Text] [Related]  

  • 8. Saquinavir in the management of HIV infection.
    Moyle G
    Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
    Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
    BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination study of Invirase and Norvir starting.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
    [No Abstract]   [Full Text] [Related]  

  • 11. [The combination of saquinavir and ddC ensures longer survival].
    Hoof T
    Dtsch Med Wochenschr; 1996 Sep; 121(37):A30. PubMed ID: 8925721
    [No Abstract]   [Full Text] [Related]  

  • 12. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection.
    Hoetelmans RM; van Essenberg M; Meenhorst PL; Mulder JW; Beijnen JH
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):235-41. PubMed ID: 9367213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.
    Gill MJ
    AIDS; 1998 Jul; 12(11):1400-2. PubMed ID: 9708428
    [No Abstract]   [Full Text] [Related]  

  • 16. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics.
    Maserati R; Villani P; Cocchi L; Regazzi MB
    AIDS; 1998 May; 12(7):815-6. PubMed ID: 9619815
    [No Abstract]   [Full Text] [Related]  

  • 18. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH studies link between saquinavir and garlic pills.
    AIDS Alert; 2002 Feb; 17(2):26. PubMed ID: 11862747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.